[New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)].
Brune
Kay
K
Klinische Pharmakologie, Universität Erlangen-Nürnberg.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005060:Europe; D005062:European Union; D006801:Humans; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment
D016861:Cyclooxygenase Inhibitors; D009288:Naproxen